SCHEMBL6413428

SCHEMBL6413428

NN=C(c1ccc(-c2cccc(C(=O)O)c2)o1)c1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.47
POLB P06746 6/20 0.43
KDM4E B2RXH2 5/20 0.43
L3MBTL1 Q9Y468 5/20 0.43
ALDH1A1 P00352 4/20 0.43
TDP1 Q9NUW8 4/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 4/20 0.40
KMT2A Q03164 4/20 0.40
RHOA P61586 1/20 0.40
RAB9A P51151 2/20 0.40
VCP P55072 1/20 0.39
LDHA P00338 1/20 0.38
CSNK2A1 P68400 2/20 0.37
CSNK2A2 P19784 1/20 0.37
CSNK2B P67870 1/20 0.37
PKM P14618 1/20 0.37
APEX1 P27695 1/20 0.37
BLM P54132 1/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6415907 0.94 BIRC5 (0.41) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6434895 0.93 BIRC5 (0.45) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6431830 0.92 BIRC5 (0.44) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6419244 0.92 BIRC5 (0.48) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6419747 0.90 BIRC5 (0.43) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6415959 0.88 BIRC5 (0.42) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6435177 0.88 LDHA (0.47) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6414854 0.86 BIRC5 (0.65) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6419710 0.86 MAPT (0.40) BIRC5POLBKDM4EL3MBTL1ALDH1A1
SCHEMBL6420382 0.86 POLB (0.48) BIRC5POLBKDM4EL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 BIRC5 2525/4885POLB 3589/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.